http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011105310-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57545 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
| filingDate | 2011-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011105310-A |
| titleOfInvention | NEUROPEPTIDE-2 RECEPTOR AGONISTS |
| abstract | 1. Neuropeptide-2 receptor agonist of formula (I)! ! where X is 4-oxo-6- (1-piperazinyl) -3 (4H) -quinazolinacetic acid (Pqa),! Y is H, acyl, substituted or unsubstituted alkyl, substituted or unsubstituted (lower) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, the residue of polyethylene glycol, PEGm-SSA, PEGm-β-SBA, PEGm- SPA or PEGm-VTS,! Y 'means H, the residue of polyethylene glycol, PEGm-SSA, PEGm-β-SBA, PEGm-SPA or PEGm-BTC,! R1 is Ile, Ala, (D) Ile, N-methyl-Ile, Aib, 1-1-Aic, 2-2-Aic, Ach or Acp,! R2 means Lys, Ala, (D) Lys, NMeLys, Nle or (Lys-Gly),! R3 is Arg, Ala, (D) Arg, N-methyl-Arg, Phe, 3,4,5-trifluoro-Phe or 2,3,4,5,6-pentafluoro-Phe,! R4 is His, Ala, (D) His, N-methyl-His, 4-MeOApc, 3-Pal or 4-Pal,! R5 is Tyr, Ala, (D) Tyr, N-methyl-Tyr, Trp, Tic, Bip, Dip, (1) Nal, (2) Nal, 3,4,5-trifluoro-Phe or 2,3,4 , 5,6-pentafluoro-Phe,! R6 is Leu, Ala, (D) Leu or N-methyl-Leu,! R7 means Asn, Ala or (D) Asn,! R8 means Leu or Trp,! R9 is Val, Ala, (D) Val or N-methyl-Val,! R10 is Thr, Ala or N-methyl-Thr,! R11 is Arg, (D) Arg or N-methyl-Arg,! R12 means Gln or Ala,! R13 is Arg, (D) Arg or N-methyl-Arg,! R14 is Tyr, (D) Tyr or N-methyl-Tyr, modified-Tyr, Phe, modified-Phe, Cha, (1) Nal, (2) Nal, C-α-methyl-Tyr or Trp, and PEGm means PEG with MM from 1 to 60 kDa,! or a pharmaceutically acceptable salt thereof. ! 2. Neuropeptide-2 receptor agonist according to claim 1 of formula (Ia)! ! where X is N-piperazin-1-yl-4- (3H) -quinazolinone-3-acetic acid (Pqa),! Y is H, acyl, substituted or unsubstituted alkyl, substituted or unsubstituted (lower) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkoxy, the residue of polyethylene glycol, PEG-SSA, PEG-β-SBA, PEG-SPA or PEG-VTC ! R1 is Ile, Ala, (D) Ile, N-methyl-Ile, Aib, 1-1-Aic, 2-2-Aic, Ach or Acp,! R2 is Lys, Ala, (D) Lys, NMeLys, Nle or |
| priorityDate | 2005-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.